Fig. 7
From: Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Summary of the consensus recommendations for the management of patients with SSc-ILD. 6MWD 6-min walk distance, CYC cyclophosphamide, DLCO diffusing capacity of the lungs for carbon monoxide, FVC forced vital capacity, HRCT high-resolution computed tomography, ILD interstitial lung disease, MMF mycophenolate mofetil, PFT pulmonary function test, PH pulmonary hypertension, SpO2 peripheral capillary oxygen saturation, SSc-ILD systemic sclerosis-associated ILD, TCZ tocilizumab